STRASBOURG, France & MONTREAL & BOSTON--(BUSINESS WIRE)--Domain Therapeutics (“Domain” or “the Company”), a global clinical-stage biopharmaceutical company developing innovative drug candidates in ...
Presentation of Phase I clinical results from DT-9081, an EP4 receptor antagonist, and preclinical data on DT-7012, a Treg depleting anti-CCR8 antibody Preclinical findings highlight immuno-oncology ...
The MarketWatch News Department was not involved in the creation of this content. -- First patient dosed in France, expanding the DOMISOL study beyond Australia -- DT--7012 is being evaluated as ...
BRYAN, Texas, March 31, 2023 (GLOBE NEWSWIRE) -- iBio, Inc. (NYSEA:IBIO) (“iBio” or the “Company”), an AI-driven innovator of precision antibody immunotherapies, today announced the progression of its ...
BEIJING, China & TOKYO--(BUSINESS WIRE)--February 1 st 2021, Biocytogen Pharmaceuticals (Beijing) Co., Ltd. ("Biocytogen") entered a strategic collaboration with LiberoThera Co., Ltd (“LiberoThera”) ...
The MarketWatch News Department was not involved in the creation of this content. -- Recent publication of three international Patent Cooperation Treaty (PCT) patent applications covering Domain's ...
First patient dosed in France, expanding the DOMISOL study beyond Australia DT‑7012 is being evaluated as monotherapy and in combination with pembrolizumab in a global clinical development program ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results